Healthy volunteers help compare generic antifungal to brand-name drug
NCT ID NCT06983665
First seen Jan 28, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study checks if a new liposomal amphotericin B (made by Sichuan Huiyu) is absorbed and processed by the body the same way as the approved drug AmBisome®. It involves 42 healthy Chinese adults who receive a single dose of each drug in random order. The goal is to see if the new version is equivalent, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jinan Central Hospital, No.105, Jiefang Road,
Jinan, Shandong, China
Conditions
Explore the condition pages connected to this study.